The potential reclassification of marijuana from a Schedule I to a Schedule III drug could significantly impact the pre-roll industry. This article explores the potential benefits of reclassification, including reduced tax burdens, increased access to banking, and opportunities for research and development. It also highlights the importance of preparing for increased competition and strategizing for future success.
Pre-rolled marijuana products are experiencing a surge in popularity, with sales exceeding $4.1 billion in 2023 and the first half of 2024, according to a study by Custom Cones USA. The study highlights the significant growth of pre-rolls, particularly infused pre-rolls, which have become the top-selling category. This trend is expected to continue as the cannabis market expands into new territories.
